The Best Stocks for 2011: Dendreon

This article is part of our "Best Stocks for 2011" series where our Foolish writers pick their top stock ideas for the year ahead. Click here to see a review of last year's picks and our 12 recommendations for the year ahead.

I'll admit it: I should have picked Dendreon (Nasdaq: DNDN  ) as my 2010 best buy. Shares are up nearly 40% this year. I didn't have confidence that its prostate cancer treatment, Provenge, would get past the Food and Drug Administration. Better yet, I should have picked it before the positive phase 3 data was announced in early 2009; shares are up more than 500% since then.

Dendreon isn't going to see those kinds of returns in 2011. Drugmakers with binary events -- like Orexigen Therapeutics (Nasdaq: OREX  ) and its obesity drug, Contrave, which is up for an FDA decision, or Exelixis (Nasdaq: EXEL  ) , which is expecting phase 3 data for its cancer drug XL184 next year -- are more likely to offer one-year multibaggers.

Then why the heck are you picking it?
Simply put, the risk is mostly gone, but there's still upside left. Sometimes a relatively safe stock with double-digit potential beats a volatile double-or-nothing stock.

At a market cap of more than $5 billion, some Provenge sales are already priced in, but shares can certainly go higher from here.

How much higher? Investors were willing to price it above $54 per share after the FDA approved Provenge in April. When investors came to their senses and realized there was still risk involved with owning a drugmaker even if it has an approved drug, shares fell substantially. Eventually though, they're bound to get back there when investors have confidence that the launch is going as planned.

A buyout kicker
Provenge could offer a buyer an extended revenue stream well after its patents expire, since it's more of a treatment than an easy-to-copy drug. Generic-less drugs are pretty much a dream for Pfizer (NYSE: PFE  ) , given its coming loss of Lipitor, or Eli Lilly (NYSE: LLY  ) , which has multiple top selling drugs coming off patent.

An acquisition may not happen in 2011; actually, I'd be a little surprised if it did. But the idea of some pharmaceutical company buying Dendreon will always be in the back of investors' minds, which should keep Dendreon from falling too much.

My guess is it'll go something like this: Dendreon signs up a big pharma as an ex-U.S. marketing partner. The pharma company uses the opportunity to better gauge the value of Provenge and makes an offer in a year or three. We've seen this story before.

About that "mostly gone" risk
Two things really hung over Dendreon in 2010: whether it could produce enough Provenge and whether Dendreon could get it paid for.

The latter seems fairly likely. Aetna (NYSE: AET  ) , Humana (NYSE: HUM  ) , Kaiser, and others have all signed off on reimbursement. And advisors to the Centers for Medicare & Medicaid Services gave the drug a more-confident-than-not vote. When the agency issues its national guidance next year, paying for the drug -- at least for on-label use -- seems pretty likely.

The issue of making Provenge isn't as cleared up since Provenge is not your typical drug. The personalized treatment requires patients' blood cells to be sent to the lab, where it's trained to elicit an immune response against the cancer before being sent to the doctor's office to be put back into the patient.

Dendreon seems to have fairly easily ramped up to its current capacity of around $10 million per month. Of course, extrapolate that out and it's only $120 million per year, a far cry from the blockbuster everyone is expecting.

In order to hit its loftier revenue goals, Dendreon must get additional capacity at its New Jersey plant approved around March and bring its new plants in Atlanta and Los Angeles plants online around mid-year.

Could it still run into snags? Absolutely; this stock is far from riskless. But with every day that goes by, investors should be a little more confident that Dendreon can hit its capacity goal. And confident investors are all that Dendreon really needs to see its shares rise.

What do you think? Is Dendreon the best stock for 2011? Take our poll and sound off on the risk-reward profile in the comments box below.

Which is the best stock for 2011? See all 12 candidates here.

Motley Fool Rule Breakers is always on the hunt for hot drug stocks and other cutting-edge picks. Click here to see all of our latest discoveries with a free 30-day trial subscription.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. Pfizer is a Motley Fool Inside Value choice. The Fool owns shares of Exelixis, which is a Motley Fool Rule Breakers selection. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool has a disclosure policy.


Read/Post Comments (2) | Recommend This Article (19)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On December 31, 2010, at 10:19 PM, JDR524 wrote:

    Provenge has significant competition coming up in a pill called abiraterone. Also, most oncologist's aren't that excited about the major hassel getting a patient treated--for now they will only be able to get the drug in centers originally involved in the trials. Dendreon is being quiet about this rate limiting step. Some fellow fools think urologists are going to get involved with Provenge. Given the 100% rate of infusion reaction and the 3% stroke risk, the urologists I've spokien to have no interest.

  • Report this Comment On January 08, 2011, at 3:32 PM, ddepperman wrote:

    Abiraterone is essentially a testosterone production blocker. Provenge works differently--as reported--by producing an immune reaction to prostate cancer cells. The thing about metastisized prostate cancer is that the cells become increasingly less responsive to testosterone, hence can grow without testosterone's stimulation. So, you die, eventually. Abiraterone is thus, not quite a competitor to provenge at all.

    Myself, I'd get my PSA checked yearly, and if it begins to increase--year-over-year, to borrow an investment phrase--I'd get very interested in the prevailing options to stop it, even when it is in the normal range. I met a man whose PSA was around 115(normal range 0-3.5) with mets everywhere, incl ureters, thus blocking kidney drainage, causing kidney failure, bone, brain etc. This ain't a pretty picture, men. Don't ignore it.

    As for provenge, the stock has run up much and frankly, I'll sit it out.

    See below. Note the inconsistency in the last sentence. If the cancer is testosterone resistant what are you doing blocking its production to fight the freakin cancer? Sounds wrongheaded.

    FROM abiraterone web site in UK:

    The male hormone testosterone stimulates prostate cancers to grow. Stopping the body making testosterone can slow the growth of the cancer, or even shrink it. Most testosterone is made by the testes but a small amount is made by other tissue in the body including the cancer itself. To make testosterone the body needs an enzyme called cytochrome P17 (CYP17). Abiraterone acetate blocks this enzyme, which stops both the testes and other tissues in the body making testosterone.

    Researchers are looking at using abiraterone treatment for men with prostate cancer that has spread to another part of the body, and who have had hormone therapy that is no longer working.

Add your comment.

DocumentId: 1413665, ~/Articles/ArticleHandler.aspx, 7/28/2014 9:18:31 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement